Development and validation of a liquid chromatography-tandem mass spectrometry assay to quantify plasma busulfan

Therapeutic Drug Monitoring

Volumn 36, Issue 2, 2014, Pages 169-174

  French, Deborah ^a   Sujishi, Kirk K ^b   Long Boyle, Janel R ^c   Ritchie, James C ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Medical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Busulfan; LC MS MS; Mass spectrometry

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; BUSULFAN; FORMIC ACID; METHANOL; WATER; ALKYLATING AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG MONITORING; ELUTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS FRAGMENTOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; TURNAROUND TIME; BLOOD; CHILD; COMPARATIVE STUDY; COST; ECONOMICS; PROCEDURES; REPRODUCIBILITY; VALIDATION STUDY;

ADULT; ALKYLATING AGENTS; BUSULFAN; CHILD; CHROMATOGRAPHY, LIQUID; COSTS AND COST ANALYSIS; DRUG MONITORING; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84897844768     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/01.ftd.0000443060.22620.cd     Document Type: Article

References (16)

1. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230
2. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42
3. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood. 1994;84:2144-2150
4. Grochow LB. Busulfan disposition: The role of therapeutic drug monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18-25
5. Malär R, Sjöö F, Rentsch K, et al. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant. 2011;15:580-588
6. Lai W-K, Pang C-P, Law L-K, et al. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem. 1998;44: 2506-2510
7. El-Serafi I, Terelius Y, Twelkmeyer B, et al. Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine. J Chrom B. 2013;913-914:98-105
8. Kellog MD, Law T, Sakamoto M, et al. Tandem mass spectrometry method for the quantification of serum busulfan. Ther Drug Monit. 2005;27:625-629
9. Oliveira dos Reis E, Vianna-Jorge R, Suarez-Kurtz G, et al. Development of a rapid and specific assay for detection of busulfan in human plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19:1666- 1674
10. Chen L, Zhou Z, Shen M, et al. Quantitative analysis of busulfan in human plasma by LC-MS-MS. Chromatographia. 2009;70:1727-1732
11. Snyder ML, Ritchie JC. Quantification of busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESIMS/ MS). Methods Mol Biol. 2010;603:129-136
12. Bunch DR, Heideloff C, Ritchie JC, et al. A fast and simple assay for busulfan in serum or plasma by liquid chromatography-Tandem mass spectrometry using turbulent flow online extraction technology. J Chrom B. 2010;878:3255-3258
13. Courtney JB, Harney R, Li Y, et al. Determination of busulfan in human plasma using an ELISA format. Ther Drug Monit. 2009;31:489-494
14. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030
15. Balasubramanian P, Srivastava A, Chandy M. Stability of busulfan in frozen plasma and whole blood samples. Clin Chem. 2001;47:766-768
16. BUSULFEX- [package insert]. Rockville, MD: otsuka America Pharmaceuticals Inc; 2011.